RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $235. This reaffirms the firm's positive outlook on the company's stock.
February 21, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating and a $235 price target on Alnylam Pharmaceuticals, indicating a strong positive outlook on the stock.
The reiteration of an Outperform rating and the maintenance of a high price target by a reputable analyst firm like RBC Capital suggests a strong vote of confidence in Alnylam Pharmaceuticals. This is likely to be viewed positively by investors, potentially leading to a short-term uptick in the stock's price as market sentiment aligns with the analyst's bullish outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100